Subgroup analysis
All results were similar in magnitude and direction among participants who reported any history of IPV at baseline. However, the estimated intervention effects were stronger in this subgroup than in the entire study sample for both PrEP uptake (aRR 4.68, 95% CI 1.64–13.33 Exploratory analysis: results among the subgroup of women with any IPV history at baseline (



Among those not already on PrEP at enrolment (All effect estimates are adjusted for matched pairs of study sites. The estimate for PrEP continuation is additionally adjusted for time since PrEP initiation. The estimates for the number of days of Wisepill opening is additionally adjusted for the number of days the participant was on PrEP and had a Wisepill device in her possession.Among those with any PrEP use during the study, that is on PrEP at enrolment or initiated during study (
